17-hydroxydocosa-7Z,10Z,13Z,15E,19Z-pentaenoic acid | 887752-12-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 17-hydroxydocosa-7Z,10Z,13Z,15E,19Z-pentaenoic acid
• 英文别名: 17-hydroxy DPAn-3；(7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosapentaenoic acid；(7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-7,10,13,15,19-pentaenoic acid
• CAS: 887752-12-7
• 化学式: C₂₂H₃₄O₃
• 分子量: 346.51
• InChiKey: NMUOVKUBSAYGMV-UCMLWGQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  顺-7,10,13,16,19-二十二碳五稀酸 在 soybean 15-lipoxygenase 作用下， 以 乙醇 为溶剂， 反应 0.25h， 生成 17-hydroxydocosa-7Z,10Z,13Z,15E,19Z-pentaenoic acid
  参考文献：
  名称：

  Controlled formation of mono- and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase

  摘要：

  Resolvins and protectins are important anti-inflammatory and pro-resolution compounds derived from the enzymatic oxidation of omega-3 fatty acids all-cis-5,8,11,14,17-eicosapentaenoic acid (EPA) and all-cis-4,7,10,13,16,19-docosahexaenoic acid (DHA). We have developed a simple, controlled method to synthesize an array of resolvin and protectin analogs from fatty acid starting materials using soybean 15-lipoxygenase. The conditions were optimized for the production of both mono-and dihydroxy derivatives, with enzyme concentration and pH found to have a significant effect on the reaction products. The methods were applied to five biologically important omega-3 and omega-6 fatty acid substrates. Mono-and dihydroxy compounds were successfully synthesized from all substrates and the products were characterized by normal phase (NP) HPLC, GC-MS, TOF-MS, UV-visible (UV-vis) spectroscopy, and NMR spectroscopy. The methods could be further applied to any polyunsaturated fatty acids containing the cis-1,4,7,10-undecatetraene moiety to produce a range of novel compounds with potential biological activity.-Dobson, E. P., C. J. Barrow, J. A. Kralovec, and J. L. Adcock. Controlled formation of mono-and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase. J. Lipid Res. 2013. 54: 1439-1447.

  DOI：

  10.1194/jlr.m036186

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010120719A1

  公开（公告）日：2010-10-21

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型利用新型resolvin化合物和其药物制剂的治疗方法。
• [EN] COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE CONSERVATION D'ORGANE
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010091226A1

  公开（公告）日：2010-08-12

  The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem cell preservation and/or survival comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, an oxylipin compound, or a combination of aspirin and an omega-3 fatty acid.

  该发明涉及减少、预防或逆转器官损伤，减少和/或预防干细胞损伤和/或死亡，增强器官保存和/或存活，或增强干细胞保存和/或存活的方法，包括给予化合物A的化合物，任何一个化合物1-49或I-III的化合物，脂氧合素化合物，氧脂素化合物，或阿司匹林和ω-3脂肪酸的组合。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
  申请人：Gjorstrup Per

  公开号：US20110190242A1

  公开（公告）日：2011-08-04

  The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound.

  该发明涉及治疗炎症性疾病的方法，包括给予公式A的化合物、任何一个公式1-49或I-III的化合物、脂氧素化合物或氧脂素化合物。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
  申请人：C.T. Resolve SARL

  公开号：EP2419399B1

  公开（公告）日：2016-03-23
• Compositions and methods for the treatment of cardiovascular disease
  申请人：Gjorstrup Per

  公开号：US20070254897A1

  公开（公告）日：2007-11-01

  The invention relates to methods of treating cardiovascular disease comprising administering a resolvin, lipoxin, or oxylipin compound.